Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. / Broliden, PA; Dahl, IM; Hast, R; Johansson, Bertil; Juvonen, E; Kjeldsen, L; Porwit-MacDonald, A; Sjoo, M; Tangen, JM; Uggla, B; Oberg, G; Hellstrom-Lindberg, E.

I: Haematologica, Vol. 91, Nr. 5, 2006, s. 667-670.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Broliden, PA, Dahl, IM, Hast, R, Johansson, B, Juvonen, E, Kjeldsen, L, Porwit-MacDonald, A, Sjoo, M, Tangen, JM, Uggla, B, Oberg, G & Hellstrom-Lindberg, E 2006, 'Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes', Haematologica, vol. 91, nr. 5, s. 667-670.

APA

Broliden, PA., Dahl, IM., Hast, R., Johansson, B., Juvonen, E., Kjeldsen, L., ... Hellstrom-Lindberg, E. (2006). Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica, 91(5), 667-670.

CBE

Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L, Porwit-MacDonald A, Sjoo M, Tangen JM, Uggla B, Oberg G, Hellstrom-Lindberg E. 2006. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 91(5):667-670.

MLA

Vancouver

Author

Broliden, PA ; Dahl, IM ; Hast, R ; Johansson, Bertil ; Juvonen, E ; Kjeldsen, L ; Porwit-MacDonald, A ; Sjoo, M ; Tangen, JM ; Uggla, B ; Oberg, G ; Hellstrom-Lindberg, E. / Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. I: Haematologica. 2006 ; Vol. 91, Nr. 5. s. 667-670.

RIS

TY - JOUR

T1 - Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes

AU - Broliden, PA

AU - Dahl, IM

AU - Hast, R

AU - Johansson, Bertil

AU - Juvonen, E

AU - Kjeldsen, L

AU - Porwit-MacDonald, A

AU - Sjoo, M

AU - Tangen, JM

AU - Uggla, B

AU - Oberg, G

AU - Hellstrom-Lindberg, E

PY - 2006

Y1 - 2006

N2 - The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome.

AB - The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome.

KW - cyclosporine A

KW - MDS

KW - ATG

KW - treatment

M3 - Article

VL - 91

SP - 667

EP - 670

JO - Haematologica-The Hematology Journal

T2 - Haematologica-The Hematology Journal

JF - Haematologica-The Hematology Journal

SN - 1592-8721

IS - 5

ER -